Orchestra BioMed Holdings, Inc.

NASDAQ•OBIO

CEO: Mr. David P. Hochman

セクター: Healthcare

業種: Biotechnology

上場日: 2020-08-04

Orchestra BioMed Holdings, Inc. operates as a biomedical innovation company. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension (HTN); and Virtue Sirolimus AngioInfusion Balloon (SAB) for the treatment of atherosclerotic artery disease. Its products also comprise FreeHold devices and minimally invasive surgery devices. The company has a collaboration agreement with Medtronic, Inc. for the development and commercialization of BackBeat CNT for the treatment of HTN in patients indicated for a cardiac pacemaker; and a strategic collaboration with Terumo Medical Corporation for the development and commercialization of Virtue SAB for the treatment of coronary and peripheral artery disease. Orchestra BioMed Holdings, Inc. is based in New Hope, Pennsylvania.

連絡先情報

150 Union Square Drive, New Hope, PA, 18938, United States

212-862-5797

orchestrabiomed.com

時価総額

$260.30M

PER (TTM)

-3.3

17.2

配当利回り

52週高値

$5.42

52週安値

$2.20

52週レンジ

75%

順位49Top 66.7%

3.2

F-Score

改良版 Piotroski 分析

5年ファンダメンタル

弱い • 3.2 / 9 ポイント

スコアレンジ (0-9)

8-9: 価値が優れている

6-7: 基礎体質が強い

4-5: 全体的に堅調

0-3: パフォーマンスが弱い

データ期間: 2021-2025

財務ダッシュボード

Q4 2025 データ

売上高

$30.92M+0.00%

直近4四半期の推移

EPS

$0.11+0.00%

直近4四半期の推移

フリーCF

-$2.30M+0.00%

直近4四半期の推移

2025 Annual 決算ハイライト

主なハイライト

Partnership Revenue Surge Partnership revenue reached 32.9M USD, up 1,539% from 2.0M USD in 2024; product revenue declined 3%.

Net Loss Narrows Net loss improved 14% to 52.7M USD in 2025, compared to 61.0M USD loss in 2024, showing operational leverage.

R&D Spending Increases Research and development expenses grew 36% to 58.2M USD, supporting pivotal studies for AVIM Therapy and Virtue SAB.

Cash Runway Extended Expect cash sufficient to fund operations into the fourth quarter of 2027 based on current estimates and expected future proceeds.

リスク要因

Continued Operating Losses History of net losses; expect continued substantial losses until commercialization success is achieved, impacting future financing ability.

Pivotal Trial Enrollment Risk BACKBEAT study enrollment completion planned mid-2026; Virtue Trial completion planned mid-2027, subject to execution risks.

Single-Source Supply Chain Highly dependent on partners and third-party vendors; currently lacks redundancy in critical supply chain for Sirolimus EFR.

Need for Future Capital Future viability dependent on ability to raise additional capital on acceptable terms, if available, to fund ongoing operations.

見通し

Advance AVIM Therapy Execution Focus on execution of key development initiatives, advancing BACKBEAT study toward regulatory submission for AVIM Therapy.

Advance Virtue SAB Trial Advance Virtue SAB into Virtue Trial, designed to support U.S. regulatory approval for coronary ISR; completion planned mid-2027.

Maximize Partnership Profitability Maximize future profitability potential by seeking multiple long-term, high-margin royalty and revenue sharing arrangements.

同業比較

売上高 (TTM)

CDXS

$70.39M

+18.6%

ENTA

$66.98M

+0.6%

IVVD

$53.43M

+110.5%

粗利益率 (最新四半期)

ENTA

100.0%

+0.0pp

SGMO

100.0%

+0.0pp

OABI

99.9%

-209.2pp

主要指標

銘柄コード	時価総額	PER (TTM)	ROE (TTM)	負債比率
IVA	$320.21M	-1.8	536.4%	32.0%
ENTA	$308.08M	-4.0	-78.6%	58.6%
OBIO	$260.30M	-3.3	-170.5%	28.2%

長期トレンド

直近4四半期

売上高

純利益

営業キャッシュフロー

4四半期売上高CAGR

229.0%

高成長

4四半期純利益CAGR

N/M

収益構造の変化

キャッシュフロー安定性

キャッシュフローに注意が必要

深度リサーチ

次回決算:2026年3月30日

EPS:-$0.38

売上高:$931.00K

財務データ

決算説明会

財務レポート

ニュース

損益計算書

バランスシート

キャッシュフロー計算書

財務比率

変化率

損益計算書	直近12ヶ月

データなし